Indeed, there is some evidence that EGFR inhibitors combined with FOLFOX in such patients are detrimental compared with FOLFOX alone (Douillard et al, 2013; Bokemeyer et al, 2015), and EGFR inhibitors should therefore not be given to patients with RAS MT tumours. The gene discussed is EGFR; the disease is neoplasm.